Multi-disciplinary patient-centered model for the expedited provision of costly therapies in community settings: the case of new medication for hepatitis C
Abstract Background In January 2015, the first interferon-free direct-acting antiviral (DAA) therapy for chronic hepatitis C virus (HCV) infection was approved for inclusion in Israel’s national basket of health services. During 2015, HCV genotype 1 patients with advanced liver fibrosis (stage F3-F4...
Main Authors: | Nitzan Avisar, Yael Heller, Clara Weil, Aviva Ben-Baruch, Shani Potesman-Yona, Ran Oren, Gabriel Chodick, Varda Shalev, Nachman Ash |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2017-09-01
|
Series: | Israel Journal of Health Policy Research |
Subjects: | |
Online Access: | http://link.springer.com/article/10.1186/s13584-017-0172-1 |
Similar Items
-
Hepatitis C virus (HCV) micro-elimination in the hospital setting: The results of the HCV Caserta hospital project
by: Alessio, L., et al.
Published: (2022) -
Reactivation of herpesvirus in patients with hepatitis C treated with direct-acting antiviral agents
by: Ghweil AA, et al.
Published: (2019-04-01) -
Lymphocyte Landscape after Chronic <i>Hepatitis C Virus</i> (HCV) Cure: The New Normal
by: Alip Ghosh, et al.
Published: (2020-10-01) -
Overview of HCV Life Cycle with a Special Focus on Current and Possible Future Antiviral Targets
by: Nathalie Alazard-Dany, et al.
Published: (2019-01-01) -
Genetic Subtypes and Natural Resistance Mutations in HCV Genotype 4 Infected Saudi Arabian Patients
by: Mariantonietta Di Stefano, et al.
Published: (2021-09-01)